Johnson and Johnson 2012 Annual Report Download - page 57

Download and view the complete annual report

Please find page 57 of the 2012 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 83

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83

Pre-Tax Profit Identifiable Assets
(Dollars in Millions) 2012(3) 2011(4) 2010(5) 2012 2011 2010
Consumer $1,693 2,096 2,342 $24,131 24,210 23,753
Pharmaceutical 6,075 6,406 7,086 23,219 23,747 19,961
Medical Devices and Diagnostics 7,187 5,263 8,272 42,926 23,609 23,277
Total 14,955 13,765 17,700 90,276 71,566 66,991
Less: Expense not allocated to segments(1) 1,180 1,404 753
General corporate(2) 31,071 42,078 35,917
Worldwide total $13,775 12,361 16,947 $121,347 113,644 102,908
Additions to Property,
Plant & Equipment
Depreciation and
Amortization
(Dollars in Millions) 2012 2011 2010 2012 2011 2010
Consumer $468 670 526 $575 631 532
Pharmaceutical 737 729 508 1,010 958 912
Medical Devices and Diagnostics 1,230 1,095 1,113 1,857 1,331 1,270
Segments total 2,435 2,494 2,147 3,442 2,920 2,714
General corporate 499 399 237 224 238 225
Worldwide total $2,934 2,893 2,384 $3,666 3,158 2,939
Sales to Customers Long-Lived Assets(6)
(Dollars in Millions) 2012 2011 2010 2012 2011 2010
United States $29,830 28,908 29,450 $35,115 23,529 23,315
Europe 16,945 17,129 15,510 25,261 19,056 16,791
Western Hemisphere excluding U.S. 7,207 6,418 5,550 3,636 3,517 3,653
Asia-Pacific, Africa 13,242 12,575 11,077 2,362 2,163 2,089
Segments total 67,224 65,030 61,587 66,374 48,265 45,848
General corporate 899 750 715
Other non long-lived assets 54,074 64,629 56,345
Worldwide total $67,224 65,030 61,587 $121,347 113,644 102,908
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2012, 2011 and 2010, the Company did not have a customer that represented 10% of total revenues.
(1) Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income)
expense. Includes expense of $0.2 billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in
2012 and 2011, respectively.
(2) General corporate includes cash and marketable securities.
(3) Includes $1,218 million of net litigation expense, which includes product liability, comprised of $658 million and $560 million in the
Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $1,163 million of in-process research and
development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices and Diagnostics
segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics
segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146
million in the Pharmaceutical, Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and
Diagnostics segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.
(4) Includes $3,310 million of net litigation expense, which includes product liability, comprised of $1,741 million and $1,569 million in
the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $656 million of net restructuring expense,
comprised of $676 million expense in the Medical Devices and Diagnostics segment and a gain of $20 million in the Pharmaceutical
segment. The Medical Devices and Diagnostics segment also includes $521 million expense for the cost associated with the DePuy
ASR™ Hip program.
(5) Includes $397 million of net litigation gain, which includes product liability expense, comprised of $447 million expense in the
Pharmaceutical segment and a gain of $844 million in the Medical Devices and Diagnostics segment. The Medical Devices and
Diagnostics segment also includes $280 million expense for the cost associated with the DePuy ASR™ Hip program.
(6) Long-lived assets include property, plant and equipment, net for 2012, 2011 and 2010 of $16,097, $14,739 and $14,553,
respectively, and intangible assets and goodwill, net for 2012, 2011 and 2010 of $51,176, $34,276 and $32,010, respectively.
Johnson & Johnson 2012 Annual Report •49